Belite Bio (BLTE) Short Interest Ratio & Short Volume

Short interest is the volume of Belite Bio shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 234,000 shares of BLTE short. Learn More on Belite Bio's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BLTE shares currently have a short interest ratio of 4.0. Learn More on Belite Bio's short interest ratio.

Belite Bio saw a decline in short interest in the month of October. As of October 31st, there was short interest totaling 234,000 shares, a decline of 13.5% from the previous total of 270,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Belite Bio: Intra-Cellular Therapies, Inc. (2.23%), Roivant Sciences Ltd. (12.38%), Jazz Pharmaceuticals plc (6.15%), Ascendis Pharma A/S (5.62%), Madrigal Pharmaceuticals, Inc. (20.77%), Legend Biotech Co. (8.70%), Elanco Animal Health Incorporated (2.81%), Viking Therapeutics, Inc. (11.92%), Cytokinetics, Incorporated (13.75%), Blueprint Medicines Co. (6.50%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

Short selling BLTE is an investing strategy that aims to generate trading profit from Belite Bio as its price is falling. BLTE shares are trading down $0.85 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Belite Bio occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BLTE, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BLTE, twice per month. The most recent reporting period available is October, 31 2024.